EUVIMEDSkopri EUVIMED
Multizentrische StudieBeobachtungsstudieOpen access · CC BY 4.0

Chemo‐Immunotherapy Rescue for High‐Risk Neuroblastoma Patients With Progressive Disease Before High‐Dose Chemotherapy: Real‐World Data From the SACHA‐France Study

Claudia Pasqualini iD, Stéphanie Proust, Gudrun Schleiermacher iD, Marion Gambart, Sarah Jannier, Arnaud Petit, Chrystelle Dupraz, Estelle Thebaud, Yves Reguerre, Lee Aymar Ndounga-Diakou iD, Salim Laghouat, Anne Sophie Defachelles iD and 1 more

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.32080 ↗

At a glance

Multizentrische Studie in Pediatric Blood & Cancer, 2025. Written by Claudia Pasqualini and 12 co-authors. Institution: Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France. Major MEDLINE topics: Antineoplastic Combined Chemotherapy Protocols, Immunotherapy, Neuroblastoma. 18 references. The full text is freely available (open access, CC BY 4.0). Funded by: Association Hubert Gouin Enfance et Cancer, Fondation du LEEM, Imagine for Margo.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Patients with high‐risk neuroblastoma (HR‐NBL) who experience disease progression (PD) during first‐line treatment prior to high‐dose chemotherapy (HDC) represent a rare and understudied subgroup, for whom treatment strategies are poorly defined and prognosis appears to be extremely poor.

Aims

We report real‐world data on the off‐label use of chemo‐immunotherapy for HR‐NBL patients with PD before HDC. The primary endpoint of our analysis is the best response during the chemo‐immunotherapy treatment.

Methods

The SACHA‐France registry prospectively documents safety and efficacy data on compassionate/off‐label treatments for patients of ≤25 years old (NCT04477681).

Results

Between January 2020 and September 2024, 13 patients with HR‐NBL received chemo‐immunotherapy due to PD before HDC, and were included in SACHA‐France. They had a median age of 3.4 years (1.3–8.0). Six patients had NMYC‐amplified disease. Five PD occurred during/end‐of‐induction chemotherapy, and eight during temozolomide‐based chemotherapy after initial insufficient metastatic response or toxicity. All but one had metastatic progression. The chemo‐immunotherapy consisted of topotecan–cyclophosphamide ( n = 9) or temozolomide–irinotecan ( n = 4), combined with dinutuximab beta (dB) for a maximum of six cycles. Objective responses (ORs) were seen in five of 13 patients (38%)—four partial responses (PR) and one complete response (CR). Three out of the five patients with PD during/end of induction had PR, including two with NMYC‐amplified tumors. Overall, six patients underwent tandem HDC, with two remaining progression‐free after 1.7 and 2.1 years, and one remaining disease‐free at 3.4 years.

Conclusion

Chemo‐immunotherapy can benefit HR‐NBL patients with PD before HDC, including those with progression during/at the end of the induction chemotherapy and NMYC amplification. These findings support its early inclusion in HR‐NBL trials.

Subjects

MeSH terms (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsImmunotherapyNeuroblastomaChildChild, PreschoolFemaleHumansInfantMaleCompassionate Use TrialsDisease ProgressionFollow-Up StudiesFrancePrognosisProspective StudiesRegistriesAntibodies, Monoclonal

Author keywords

chemo‐immunotherapyhigh‐dose chemotherapyhigh‐risk neuroblastomaprogressive diseasereal‐world data

Substances

dinutuximabAntibodies, Monoclonal

Authors and institutions

  • Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
  • Department of Pediatric Oncology, University Hospital, Angers, France.
  • SIREDO Oncology Center (Care, Innovation and Research for Children and AYA With Cancer); RTOP (Recherche Translationelle en Oncologie Pediatrique), U830 INSERM, Institut Curie, PSL Research University, Paris, France.
  • Department of Pediatric Oncology, Toulouse University Hospital, Toulouse, France.
  • Pediatric Onco-Hematology Unit, University Hospital of Strasbourg, Strasbourg, France.
  • Department of Pediatric Hematology and Oncology, Hôpital Armand Trousseau, Paris, France.

ORCID profiles: Claudia Pasqualini, Gudrun Schleiermacher, Lee Aymar Ndounga-Diakou, Anne Sophie Defachelles, Pablo Berlanga

Funding

  • Association Hubert Gouin Enfance et Cancer
  • Fondation du LEEM
  • Imagine for Margo
  • Fight Kids Cancer

Cite

APA

Pasqualini, C., Proust, S., Schleiermacher, G., Gambart, M., Jannier, S., Petit, A., Dupraz, C., Thebaud, E., Reguerre, Y., Ndounga-Diakou, L. A., Laghouat, S., Defachelles, A. S., & Berlanga, P. (2025). Chemo‐Immunotherapy Rescue for High‐Risk Neuroblastoma Patients With Progressive Disease Before High‐Dose Chemotherapy: Real‐World Data From the SACHA‐France Study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32080

Vancouver

Pasqualini C, Proust S, Schleiermacher G, Gambart M, Jannier S, Petit A, et al. Chemo‐Immunotherapy Rescue for High‐Risk Neuroblastoma Patients With Progressive Disease Before High‐Dose Chemotherapy: Real‐World Data From the SACHA‐France Study. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32080

BibTeX
@article{Pasqualini2025,
  author = {Pasqualini, Claudia and Proust, Stéphanie and Schleiermacher, Gudrun and Gambart, Marion and Jannier, Sarah and Petit, Arnaud and Dupraz, Chrystelle and Thebaud, Estelle and Reguerre, Yves and Ndounga-Diakou, Lee Aymar and Laghouat, Salim and Defachelles, Anne Sophie and Berlanga, Pablo},
  title = {Chemo‐Immunotherapy Rescue for High‐Risk Neuroblastoma Patients With Progressive Disease Before High‐Dose Chemotherapy: Real‐World Data From the SACHA‐France Study},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.32080}
}
Start for free →